SEC Filing Summary: Form 13F Information Table
Business Context and Reporting Period
Company: Alphabet Inc.
Filing Type: Form 13F Information Table (Quarterly Report of Holdings)
Reporting Period: As of March 31, 2026
Context: This filing discloses Alphabet Inc.'s equity holdings in other public companies as of the end of the first quarter of 2026. It does not report Alphabet's own operating results, revenue, or cash flow.
Key Financial Metrics and Holdings
The filing details Alphabet's investment portfolio, listing the issuer, class of security, CUSIP, total value, and number of shares held. Voting authority is predominantly "Sole" (DFND 1) or "Shared" (DFND 2/3).
| Issuer | Value (USD) | Shares Held | Voting Authority |
|---|---|---|---|
| CME Group Inc | $1,029,005,307 | 3,484,020 | Shared (DFND 2) |
| Planet Labs PBC | $985,206,582 | 35,248,893 | Shared (DFND 2) |
| Arm Holdings PLC | $296,627,404 | 1,960,784 | Shared (DFND 2) |
| Revolution Medicines Inc | $320,198,056 | 3,292,525 | Sole (DFND 1) |
| Prime Medicine Inc | $57,637,493 | 16,562,498 | Sole (DFND 1) |
| Freshworks Inc (Total) | $130,139,343 | 16,206,643 | None / Shared |
| UiPath Inc | $78,081,141 | 7,034,337 | Shared (DFND 3) |
Note: The table above highlights select major holdings. The full filing lists 28 distinct positions including biotech firms (e.g., Beam Therapeutics, Sana Biotechnology) and tech companies (e.g., Figma, GitLab).
Material Changes and Comparisons
The filing text provided does not contain data for the prior comparable period (December 31, 2025). Therefore, material changes in position size, new acquisitions, or divestitures cannot be calculated from this document alone.
Guidance, Outlook, and Risks
Management Commentary: None provided. Form 13F is a regulatory disclosure of holdings and does not include management discussion, financial guidance, or strategic outlook.
Risks and Contingencies: The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness. No specific risk factors regarding the portfolio are detailed in this text.
Key Facts for Investor Verification
- Portfolio Concentration: Verify if the top holdings (CME Group, Planet Labs, Arm Holdings) represent a significant portion of Alphabet's total investable assets.
- Biotech Exposure: Confirm the aggregate value of the numerous biotechnology positions (e.g., Beam, Relay, Sana, Revolution Medicines) to assess sector risk.
- Voting Rights: Note the mix of "Sole," "Shared," and "None" voting authority, which may indicate the use of external fund managers or specific investment vehicles for certain holdings.
- Period Accuracy: Ensure the reporting date of March 31, 2026, aligns with the investor's analysis timeframe, as this is a future-dated filing relative to current real-time data.